Alterazione del sistema dei cannabinoidi endogeni nel liquido cerebrospinale di pazienti affetti da epilessia parziale di nuova diagnosi

A. Romigi; M. Bari; F. Placidi; M. G. Marciani; F. Torelli; F. Izzi; C. Prosperetti; S. Zannino; M. Maccarrone

Alterazione del sistema dei cannabinoidi endogeni nel liquido cerebrospinale di pazienti affetti da epilessia parziale di nuova diagnosi

Translated title of the contribution: The endocannabinoid system is disregulated in untreated partial epilepsy: CSF findings

A. Romigi, M. Bari, F. Placidi, M. G. Marciani, F. Torelli, F. Izzi, C. Prosperetti, S. Zannino, M. Maccarrone

Research output: Contribution to journal › Article › peer-review

Abstract

Experimental evidence shows that the administration of the endocannabinoid anandamide (AEA) can antagonize epileptic discharges in the hippocampal tissue of animal models. In this report, we measured the levels of AEA and the levels of the other endocannabinoid 2-arachidonoylglycerol (2-AG) in the cerebrospinal fluid (CSF) of drug-naïve patients with partial epilepsy.We found a significant reduction of AEA (down to ∼20%) in the CSF of epileptic patients compared with healthy controls (P <0.01). Instead, 2-AG levels were not affected (P = 0.48) and no correlation was found between AEA and either disease duration or patient age.Our results support the hypothesis of a different involvement of endocannabinoids in epilepsy.

Translated title of the contribution	The endocannabinoid system is disregulated in untreated partial epilepsy: CSF findings
Original language	Italian
Pages (from-to)	259-260
Number of pages	2
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	138
Publication status	Published - 2008

ASJC Scopus subject areas

Clinical Neurology

Cite this

@article{3bbf26f7a4c04240badd154368faca03,

title = "Alterazione del sistema dei cannabinoidi endogeni nel liquido cerebrospinale di pazienti affetti da epilessia parziale di nuova diagnosi",

abstract = "Experimental evidence shows that the administration of the endocannabinoid anandamide (AEA) can antagonize epileptic discharges in the hippocampal tissue of animal models. In this report, we measured the levels of AEA and the levels of the other endocannabinoid 2-arachidonoylglycerol (2-AG) in the cerebrospinal fluid (CSF) of drug-na{\"i}ve patients with partial epilepsy.We found a significant reduction of AEA (down to ∼20%) in the CSF of epileptic patients compared with healthy controls (P <0.01). Instead, 2-AG levels were not affected (P = 0.48) and no correlation was found between AEA and either disease duration or patient age.Our results support the hypothesis of a different involvement of endocannabinoids in epilepsy.",

keywords = "2-arachidonoylglycerol, Anandamide, Endocannabinoids, Partial epilepsy",

author = "A. Romigi and M. Bari and F. Placidi and Marciani, {M. G.} and F. Torelli and F. Izzi and C. Prosperetti and S. Zannino and M. Maccarrone",

year = "2008",

language = "Italian",

pages = "259--260",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "138",

}

TY - JOUR

T1 - Alterazione del sistema dei cannabinoidi endogeni nel liquido cerebrospinale di pazienti affetti da epilessia parziale di nuova diagnosi

AU - Romigi, A.

AU - Bari, M.

AU - Placidi, F.

AU - Marciani, M. G.

AU - Torelli, F.

AU - Izzi, F.

AU - Prosperetti, C.

AU - Zannino, S.

AU - Maccarrone, M.

PY - 2008

Y1 - 2008

N2 - Experimental evidence shows that the administration of the endocannabinoid anandamide (AEA) can antagonize epileptic discharges in the hippocampal tissue of animal models. In this report, we measured the levels of AEA and the levels of the other endocannabinoid 2-arachidonoylglycerol (2-AG) in the cerebrospinal fluid (CSF) of drug-naïve patients with partial epilepsy.We found a significant reduction of AEA (down to ∼20%) in the CSF of epileptic patients compared with healthy controls (P <0.01). Instead, 2-AG levels were not affected (P = 0.48) and no correlation was found between AEA and either disease duration or patient age.Our results support the hypothesis of a different involvement of endocannabinoids in epilepsy.

AB - Experimental evidence shows that the administration of the endocannabinoid anandamide (AEA) can antagonize epileptic discharges in the hippocampal tissue of animal models. In this report, we measured the levels of AEA and the levels of the other endocannabinoid 2-arachidonoylglycerol (2-AG) in the cerebrospinal fluid (CSF) of drug-naïve patients with partial epilepsy.We found a significant reduction of AEA (down to ∼20%) in the CSF of epileptic patients compared with healthy controls (P <0.01). Instead, 2-AG levels were not affected (P = 0.48) and no correlation was found between AEA and either disease duration or patient age.Our results support the hypothesis of a different involvement of endocannabinoids in epilepsy.

KW - 2-arachidonoylglycerol

KW - Anandamide

KW - Endocannabinoids

KW - Partial epilepsy

UR - http://www.scopus.com/inward/record.url?scp=77953148361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953148361&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:77953148361

SN - 0394-560X

SP - 259

EP - 260

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

IS - 138

ER -

Alterazione del sistema dei cannabinoidi endogeni nel liquido cerebrospinale di pazienti affetti da epilessia parziale di nuova diagnosi

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this